PTPRC

Across TCGA pan-cancer cohorts, PTPRC Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated PTPRC data layer compared with 23 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PTPRC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRC expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

ESCA, CESC, and UCEC are the cancer types where PTPRC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.162	0.707	<.001	36	view →
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
UCEC	DFS	Median	III,IV	0.922	0.525	.020	18	view →
READ	OS	Median	II,III,IV	0.198	0.829	.001	15	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
THCA	DFS	Median	All	0.161	0.829	.007	9	view →
SKCM	OS	Median	IV	0.415	0.861	.014	5	view →
LUAD	DFS	Median	II,III,IV	1.000	0.626	.030	4	view →
GBM	DFS	Median	All	0.082	0.244	.031	3	view →
HNSC	OS	Median	III,IV	1.000	0.353	.028	3	view →
LGG	DFS	Median	All	0.579	0.835	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PTPRC–ESCA (OS)

Open the ESCA breakdown →